 Part B: 1 BRCA12 mutation cohort: Patients with advanced germline BRCA12 mutant solid tumours; 2 Sporadic cancers cohort: This cohort will include advanced sporadic cancers that are not known to harbour germline BRCA12 mutations, but which may harbour homologous recombination HR defects, e.g. advanced TNBC, CRPC and HGSOC, and those with somatic mutations or other aberrations known to result in a hyperactivated PI3K-AKT pathway. 